InvestorsHub Logo
Followers 10
Posts 504
Boards Moderated 0
Alias Born 04/20/2016

Re: None

Monday, 01/30/2017 3:25:07 PM

Monday, January 30, 2017 3:25:07 PM

Post# of 233768
Supplementing Pourhassan with Carracciolo is a good start. However, Pourhassan does not have the knowledge, background, or experience to be involved in the management of a clinical stage biopharma company such as Cytodyn, and should be replaced with someone who possesses such qualities. The .75 stock price, for a company in multiple Phase III trials for a much needed monoclonal antibody that could become the SOC for HIV, conclusively demonstrates the market (and likely FDA) lacks confidence in Cytodyn's current CEO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News